U.S. Administrative Headquarters
Morris Corporate Center III, 400 Interpace Parkway
Tel: 1 (862) 261-7000
About Allergan, Inc.
Allergan plc (AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry.
We’re Looking for the World’s Best
At Allergan, we are committed to recruiting and retaining the industry’s best and brightest employees and are proud to offer opportunities for military veterans at all levels across our company. We offer business, scientific, technical, engineering, sales & marketing and a variety of other positions here in the U.S. and around the world.
At Allergan, you will find an entrepreneurial style work environment where employees and employee teams are encouraged to apply their unique talents to grow, contribute, innovate and excel. We welcome your ideas. We provide the support, resources and encouragement that enable you to take your career to new heights. We focus on challenging you, challenging ourselves and driving success.
Commit to your future and join us. Learn more about our exciting career opportunities at www.allergan.com/careers.
Founder: Gavin S. Herbert
CEO: Brenton L. Saunders
CFO: Maria Teresa Hilado
Please click here for clinical trial information.
850 articles with Allergan, Inc.
Allergan Declares First Quarter 2018 Cash Dividend of $0.72 Per Ordinary Share and Provides Annual General Meeting of Shareholders Updates
Allergan also announced that its 2018 Annual General Meeting of Shareholders will be held on May 2, 2018 in Dublin, Ireland.
Elastagen's revolutionary technology is based on recombinant human tropoelastin, the precursor of elastin which is a key component of youthful skin.
The ACHIEVE I study included 1327 U.S. adult patients.
Allergan Reports Solid Finish to 2017 With 12% Increase in Fourth Quarter GAAP Net Revenues to $4.3B
Allergan today reported its fourth quarter and full-year 2017 continuing operations performance.
Mr. Walsh currently serves as the Executive Vice President and Chief Financial Officer at Catalent, a role he assumed in 2008.
FDA Approves Allergan's AVYCAZ (ceftazidime and avibactam) for the Treatment of Patients With Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
Allergan today announced that the FDA has approved Allergan's sNDA to expand the approved use of AVYCAZ.
KaNDy Therapeutics is a clinical-stage company that is focused on female sex-hormone related conditions.
1/23/2018The year is already off to a good start with mergers and acquisitions in the biopharma industry.
European Commission Approves Amgen and Allergan's Mvasi (Biosimilar Bevacizumab) for the Treatment of Certain Types of Cancer
The EC approved MVASI based on a comprehensive data package that demonstrated MVASI and bevacizumab are highly similar, with no clinically meaningful differences in terms of the efficacy, safety and immunogenicity between the products.
Analysts feel the company's profit potential is starting to improve following a year in which its shares fell by more than 21%.
The U.S. Patent & Trademark Office is paving the way for generic challengers to J&J's prostate cancer drug Zytiga.
Ironwood and Allergan Announce Settlement with Sun Pharma Resolving LINZESS (linaclotide) Patent Litigation
Pursuant to the terms of the settlement, Ironwood and Allergan will grant the wholly-owned subsidiaries of Sun Pharma a license to market a generic version of LINZESS in the United States beginning on February 1, 2031.
1/8/2018As a result, the company will cut 300 jobs, primarily in Massachusetts and Connecticut.
Allergan today announced it intends to release fourth quarter and full year 2017 financial results on Tuesday, February 6, 2018, prior to the open of U.S. Financial Markets.
Allergan Provides 2018 Preliminary Financial Outlook for Select Income Statement Categories and Other Updates at 36th Annual J. P. Morgan Conference
Allergan is providing its 2018 preliminary financial outlook and other financial updates at the 36th annual J.P. Morgan Healthcare Conference in San Francisco today.
1/4/2018Allergan will cut about 5 percent of its workforce, as the company looks to cut costs due to increased pipeline competition and loss of exclusivity on some products.
Kessler Topaz Represents Investors in $290M Total Settlement Recovery Reached with Valeant Pharmaceuticals and Bill Ackman’s Pershing Square Over Insider Trading Claims
In settling the claims, Valeant and Pershing Square agreed to jointly pay a total of $290M for all involved investors.
From around 2014 through 2016, Valeant seemingly had a crisis story per week, ranging from insider trading to channel stuffing
Allergan Release: FDA Accepts NDA for Seysara (Sarecycline) for the Treatment of Moderate to Severe Acne
Allergan and Paratek Pharma today announced that the FDA has accepted a NDA to review Seysara for the treatment of moderate to severe acne vulgaris in patients 9 years of age and older.
In this study, the primary efficacy objective was met for both Cariprazine 1.5mg and 3mg dose groups.